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PET imaging in breast cancer
Evangelia V. Skoura, Ioannis E. Datseris
A B S T R A C T
The application of Positron Emission Tomography (PET) using 2-[F18] fluoro-2-de-
oxy-D-Glucose (FDG) and the more recently fused technique of Computerized To-
mography and PET (PET/CT) in patients with breast cancer is reviewed. Their role 
in diagnosis of primary tumour, staging, chemotherapy monitoring and radiotherapy 
planning, follow-up and restaging is introduced. The advantages of combination of 
anatomical and functional images are emphasized and the comparison with other im-
aging techniques is highlighted.
I N T R O D U C T I O N
During the past decade, the application of positron emission tomography (PET) 
has remarkably improved the management of cancer patients. The radiotracer most 
widely used in clinical practice is the glucose analogue 2-[F18] fluoro-2-deoxy-D-glu-
cose (FDG). PET is showing increasing value in the distinction between malignant and 
benign lesions, in disease staging and re-staging and in therapy planning. Combined 
PET/CT systems have recently been developed and allow functional PET and anatomi-
cal CT images to be acquired in one session and rapidly co-registered [1].
In this review, we evaluate the possible impact of PET and PET/CT on breast 
cancer diagnosis and on clinical management of breast cancer patients, in comparison 
with conventional imaging modalities, such as mammography, Computed Tomography 
(CT) and Magnetic Resonance Imaging (MRI) imaging.
D I A G N O S I S  O F  P R I M A R Y  T U M O U R
At present, diagnosis of primary breast cancer is principally based on mammogra-
phy. Although this technique has a high sensitivity (85-90%), its major limitation is a 
low specificity and a low positive predictive value (10-35%) [1,2]. Mammography has 
also a low negative predictive value in patients with dense breasts or breast implants or 
after previous treatment for breast cancer [3].The false negative results in these women 
range between 25% and 45% [4]. Therefore, other non-invasive diagnostic imaging 
methods have been evaluated. The specificity of ultrasound is reported to be superior 
to that of mammography, especially in distinguishing solid and cystic lesions [5]. ΜRI 
imaging presents a sensitivity higher than 90%, but its specificity is lower than that of 
mammography [6]. In conclusion, the combination of these examinations is not suf-
ficiently conclusive to significantly reduce the use of invasive diagnostic procedures 
in the primary diagnosis of breast cancer [1].
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Several investigations have been conducted to assess the 
role of [18F] FDG-PET in detecting primary breast cancer. 
PET has yielded very encouraging results, showing a diagno-
stic sensitivity ranging between 80% and 96% and a specificity 
between 83% and 100% [7-10] but its ability to detect breast 
cancer greatly depends on tumour size. Regarding small tu-
mours, only 68.2% of breast carcinomas at stage pT1 (<2cm) 
are correctly identified compared to 91.9% of these at stage 
pT2 (>2-5cm) [7]. because of its limited spatial resolution, 
PET is not recommended for lesions smaller than 1cm in 
diameter [11].
In addition, PET imaging accuracy is affected by tumour 
histology. Invasive lobular carcinomas are more often false 
negative (65.2%) than invasive ductal carcinomas (23.7%) 
[7]. Indeed there is higher glucose metabolism for invasive 
ductal carcinomas (median SUV of 5.6) versus invasive lobular 
carcinomas (median SUV of 3.8) [12]. Standardized uptake 
value (SUV) is a commonly used parameter in PET imaging 
and it is defined as the fractional uptake of FDG relative to 
the injected activity normalized to the body weight [13].
The identification of multifocal or multicentric breast 
cancer plays an important role in decisions about therapy, as 
it limits breast-conserving surgery. The sensitivity of PET is 
quite low, but it is twice as sensitive in detecting multifocal 
lesions (sensitivity 63%, specificity 95%) than the combination 
of mammography and ultrasound (sensitivity 32%, specificity 
93%) [7,8].
The diagnosis of in situ carcinomas has increased over the 
past decade, but data suggest that PET imaging cannot con-
tribute to an improved diagnosis of non-invasive breast cancer. 
Nevertheless, it is important to note that focally increased 
FDG accumulation provides a high positive predictive value 
(96.6%) in diagnosing breast cancer [7].
In general, benign breast masses display low FDG uptake. 
About 10% of fibroadenomas take up FDG. Fibrocystic 
changes often do not reveal any significant FDG uptake, 
even though some false positive imaging results have been 
obtained in proliferative dysplasia (diffuse uptake), ductal 
ectasia, tubular angiomyoepithelioma and cystosarcoma phyl-
lodes [14]. False positive results have also been observed in 
infectious and inflammatory lesions, including hemorrhages 
after biopsy or surgery [14].
The dual system PET/CT solves the problem of lesion 
localization -fusing the two imaging modalities-and allows 
differentiation between pathological uptake and the normal 
physiological variants of radiotracer uptake (in the urinary 
tract, bowel, brown fat and muscles) [3]. The frequency of 
definite lesion characterization is increased by 38% (from 
65% to 90%) with PET/CT as compared to PET and the 
frequency of equivocal lesion characterization is decreased 
by 83% [15].
A considerable number of studies have shown the value 
of FDG PET imaging in breast cancer patients. However, 
PET imaging may not be used as a routine application for 
evaluation of primary breast tumors, because of the low 
sensitivity, but it provides a high positive predictive value to 
represent malignancy in patients that present metabolically 
active lesions [13].
P R E - O P E R A T I V E  S T A G I N G
Pre-operative staging of breast cancer is extremely impor-
tant as it influences treatment decisions [11].
In the TNM staging system, T stage depends on the precise 
size of the primary tumour. Conventional imaging techniques 
such as mammography and ultrasonography are better than 
PET in determining tumour size (13). MRI can detect small 
tumours 2-3mm while sensitivity of PET for tumours less than 
1cm in diameter (T1a &b) is 25% [13]. Therefore PET has not 
adequate spatial resolution for the determination of T stage.
The axillary lymph node status is considered the single 
most important prognostic indicator in patients with breast 
cancer. Clinical examination and conventional imaging tech-
niques are generally unreliable for the determination of N 
stage. Recent experience with lymphoscintigraphy has shown 
that the intraoperative gamma probe has a greater than 90% 
accuracy for detecting sentinel lymph nodes [16].
In anatomic based imaging modalities, such as CT, ul-
trasound and MRI, the size of a particular lymph node is of 
crucial importance in determining the tumour involvement. 
Acccordingly, lymph node enlargement over 1 cm in diameter 
is the decisive criterion. In contrast, metabolic imaging with 
PET seems to provide more specific information based on 
detecting increase glucose consumption of cancer tissue. The 
results of most studies indicate that PET is highly sensitive and 
specific for the presence of nodal disease in the axilla with a 
sensitivity ranging from 79% to 100%, a specificity ranging 
from 50% to 100% and an accuracy ranging from 77% to 
89.8% [8,17-20]. Small axillary metastases were frequently 
missed,suggesting that detection of micrometastases and small 
tumour-infiltrated lymph nodes is limited by the currently 
achievable spatial resolution of PET (approximately 6-8mm). 
PET has been found to be insensitive for minute foci of meta-
static disease and therefore cannot replace lymphoscintigraphy 
and sentinel lymph node mapping [21]. Compared to conven-
tional imaging modalities, PET seems to be more accurate in 
determining the locoregional lymph node status, particulary 
in women with locally advanced breast cancer although it does 
not allow determination of the number of tumour-involved 
lymph nodes. In lymph node regions in which histological or 
clinical follow-up results revealed the existence of malignancy, 
PET demonstrated definitely positive findings in all of them 
while CT showed positive, equivocal and negative findings 
in 56%, 24% and 20%, respectively [15]. In a PET/CT study 
aiming at staging breast cancer patients, sensitivity, specificity 
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and accuracy in detecting lymph node metastases were 80%, 
90% and 86.7%, respectively. In comparison with PET alone.
PET/CT provided additional information in terms of detection 
and lesion localization in 46% of cases, [22].
Although there are only a few studies available which di-
rectly compare the diagnostic accuracy of PET with sentinel 
node biopsy in breast cancer patients, sentinel node biopsy 
seems to be the method of choice in early stages of disease, 
whereas PET excels with a high diagnostic accuracy in locally 
advanced stages [23].
Detection of internal mammary lymph nodes has long been 
a challenge for imaging modalities, as metastases in this region 
are often clinically occult [15]. The sensitivity, specificity and 
accuracy of PET seems to be higher than those of CT (85%, 
90% and 88% vs 54%, 85% and 73%, respectively) [24]. Using 
PET/CT findings of abnormal focal uptake in the region of 
the internal mammary chain appear to be more frequent than 
when using PET alone. PET/CT can improve the diagnostic 
confidence to almost 100%, in the internal mammary region 
[11,15]. This may be the result of a higher localisation accuracy 
of PET/CT in comparison with PET, allowing the detection 
of lesions considered on PET alone as showing non-specific 
uptake [11].
Another advantage of PET in breast cancer staging is 
that, being a non-invasive technique, allows the study of 
all lympatic basin of the breast (axilla, supraclavicular and 
mammary chain) and it permits the characterization of breast 
lesions and the complete viewing of the entire body in a single 
examination [14].
M stage is characterised by the presence of distant me-
tastases. In breast cancer, distant metastases are frequently 
found in lymph nodes, lungs, liver and bones. Therefore, chest 
X-ray, abdominal ultrasound, bone scintigraphy, CT and MRI 
are useful for staging. As PET imaging became more easily 
available, different groups of investigators have evaluated the 
role of PET in staging breast cancer. In a study, PET imaging 
correctly identified 97% of patients with lymph node involve-
ment, 100% of those with bone metastases, 83% of those 
with lung metastases and 100% of those with liver metastases 
[25]. Furthermore, the diagnostic accuracy of PET imaging 
was compared with CT and MRI. PET detected additional 
lymph node (27%) and bone metastases (46%) missed by 
conventional imaging techniques [25]. Even though CT and 
MRI imaging show superior spatial resolution, PET provides 
more accurate information in discriminating between viable 
tumour, fibrotic scar or necrosis. PET can identify metastatic 
disease with a sensitivity and specificity of 85%-86% and 79%-
90%, respectively [26,27] where the sensitivity and specificity 
of chest X-ray, bone scintigraphy and ultrasound of the abdo-
men are 36% and 95% respectively [27]. With respect to the 
location of metastases, the sensitivity of PET was superior in 
detecting pulmonary metastases and particularly mediasti-
nal lymph node metastases compared with chest X-ray. The 
sensitivity of PET in detecting bone and liver metastases is 
of the same magnitude compared with bone scintigraphy and 
ultrasound of the abdomen, respectively [27].
Particular attention should be paid to skeletal involvement 
because 8-10% of breast cancer patients develop skeletal 
metastases early in their disease and the frequency of bone 
metastases is around 70% in patients with advanced disease 
[14]. bone scintigraphy visualises the osteoblastic response 
to bone destruction by cancer cells, while PET visualises pri-
marily the metabolic activity of the tumor cells [14]. Clinical 
studies have demonstrated that PET detects significantly more 
lesions than bone scintigraphy. However, this higher FDG 
uptake was confined to osteolytic lesions [28]. Therefore, PET 
is superior to bone scintigraphy in the detection of osteolytic 
not osteoblastic breast cancer metastases [28].
There is evidence that PET imaging in breast cancer 
patients leads to a shifting in clinical staging in 36% and in a 
change in the treatment strategy in 60% of patients, respec-
tively as a result of a higher number of distant metastases [29]. 
The advantage of whole-body PET imaging is its ability to 
detect metastases in different sites and organs, whereas vari-
ous other methods need to be added when using conventional 
imaging [13].
PET/CT adds incremental diagnostic confidence to PET 
in 33% to 100% of cases, depending on location of metastases 
with the exception of the liver (0%) [15]. Equivocal lesions 
decrease by 83% with PET/CT in comparison with PET while 
PET/CT showed definitely positive foci in 28% of cases with 
equivocal or negative CT findings. The sensitivity, specificity 
and accuracy of PET/CT are 87%, 62% and 83%, respectively 
compared with 68%, 69% and 68% of CT alone [15].
In a retrospective analysis of the impact of PET on clinical 
management of patients with breast cancer, it was found that 
PET was 69% sensitive and 80% specific in predicting clini-
cal stage at 6 months and there was a significant association 
between PET results and clinical outcome [30]. More specifi-
cally, 69% of the patients who demonstrated progression at 
6 months were PET positive while 80% of the patients who 
were stable or improving at 6 months were PET negative [31]. 
PET influenced treatment decisions in 74% of the patients 
referred for study [30].
T R E A T M E N T  M O N I T O R I N G
Up to now, anatomical imaging modalities are mostly used 
to evaluate response to treatment, by evaluating changes in 
tumour size. Nevertheless, these modalities do not usually 
allow the determination of early response or differentiation 
between viable tumour tissue and scar tissue. PET imaging 
seems highly useful in monitoring therapeutic effects at an 
earlier stage in the course of treatment. It is known that an-
ticancer treatment primarily influences tumour metabolism, 
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which only at a later stage is followed by a decrease in tumour 
mass [14]. A reduction in the FDG uptake (SUV) can predict 
for a subsequent decrease in the diameter of the tumour [32]. 
Unchanged or enhanced FDG uptake indicates tumour pro-
gression [11]. Early identification of non-responders would 
significantly improve patient management by reducing the 
use of ineffective therapies, preventing prolonged side-effects, 
reducing the delay in initiation of more effective treatment 
and minimizing costs [14].
While data on PET monitoring in radiotherapy and chemo-
therapy of advanced disease are in general inadequate some 
valid data are available regarding the monitoring of primary 
chemotherapy.
P R I M A R Y  ( N E O - A D J U V A N T ) 
C H E M O T H E R A P Y 
It is increasingly used for patients with locally advanced 
breast cancer as it can increase the rate of breast-conserving 
surgery by preoperatively reducing the tumor volume [34]. 
Patients with complete pathological response after neoadju-
vant therapy have significantly higher disease-free and overall 
survival rates than non-responders [13]. Approximately 70% of 
the patients undergoing primary chemotherapy show clinical 
response, but only 20-30% demonstrate partial or complete 
response at histopathological level [33]. Therefore, the thera-
peutic effect cannot be accurately evaluated until definitive 
breast surgery is performed [13].
because of the significant side-effects of chemotherapy, 
there is a need for early identification of non-responding pa-
tients [13]. There are now published studies addressing the role 
of PET in predicting response early in the course of therapy. 
Patients with newly diagnosed primary breast cancer begin-
ning chemohormonotherapy, underwent a baseline PET and 
follow-up PET scans during the first three cycles of treatment 
[34]. Responders demonstrated progressive decreases in FDG 
uptake by the tumours, to a mean of 52.4% of baseline values 
at 63 days,while non-responders had no significant change 
in tumor FDG uptake.Another study has demonstrated that 
the decrease in FDG uptake is a marker of tumour response 
and that PET imaging of primary metastatic breast cancer 
after a single course of chemotherapy may predict treatment 
response with a sensitivity of 90% and a specificity of 74% 
[35]. With a threshold defined as a decrease below 55% of 
the baseline FDG uptake all eventually responded patients 
were identified after the first course of therapy (sensitivity 
100%, specificity 85%) [36]. Increased tracer uptake after the 
first cycle did not exlude a partial tumor response;only after 
the second chemotherapy cycle PET was able to distinguish 
between complete and partial/no response [37]. PET seems 
to be more accurate than conventional imaging modalities 
for predicting outcome in breast cancer patients who were 
reevaluated after primary treatment (accuracy, positive and 
negative predictive values of 90%, 93% and 84% respectively 
vs 75%, 85% and 59% respectively) [38]. The advantage of 
PET/CT compared with PET alone is that it may improve the 
accuracy in the evaluation of treatment response by directly 
defining metabolic and morphological changes [11].
F D G - P E T  B E F O R E  A N D  A F T E R 
R A D I O T H E R A P Y
A PET study before radiotherapy not only allows evalua-
tion of metabolic tumour activity but also permits treatment 
planning. The high rate or recurrences within the primary 
target volume in some tumours necessitates a dose escala-
tion to increase the probability of tumour control. However, 
radiotoxicity to healthy tissue limits this strategy [39]. The role 
of PET in determining tumour extension and its relationship 
with surrounding tissues, is limited but PET/CT is changing 
this role by integrating the information on tumour morphology 
provided by CT with that on its metabolism [11]. PET/CT can 
play a major role by correctly staging the disease and provid-
ing an accurate estimate of tumour volumes to be selectively 
irradiated [11].
An early decrease in FDG uptake does not necessarily 
indicate a good prognosis.Immediately after completion of 
radiation therapy, PET may demonstrate continued uptake 
in the periphery of the tumour.This FDG accumulation was 
found to correlate pathologically with the formation of a 
fibrous pseudocapsule rather than residual disease [39]. A 
major problem of post-radiation therapy PET is that normal 
tissues can manifest radiotherapy induced toxicity to dif-
ferent degrees within a few days or even months.because 
of these effects, significantly increased FDG uptake can be 
seen in selected soft tissue regions that have been irradiated 
[40]. Some studies suggest that a fair compromise may be to 
recommend PET imaging 4-6 months after completion of 
radiation, if possible [39].
Radiotherapy response will, of course, be associated with 
reduction in tumour size. The definition of complete response 
can, however, be problematic as complete disappearance of the 
tumour may occur only rarely, and more commonly residual 
tissue, whether it be scar or residual tumour, remains [33]. 
PET can identify changes in glucose uptake after treatment 
and may prove to be a better indicator of a favourable response 
to therapy [39].
F D G - Ρ Ε Τ  D U R I N G  H O R M O N E  T H E R A P Y 
Some researchers have used 18F-labelled oestradiol and 
other radiolabelled oestrogens and progestins as radio-tracers 
[40,41]. In a study, fluoro-oestradiol PET and FDG-PET was 
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bone metastases. In contrast, osteoblastic metastases show a 
lower metabolic activity and are frequently undetectable by 
PET [42].
The breast cancer metastases in the axilla and the brachial 
plexopathy are difficult to assess on conventional anatomic 
imaging. MRI detected 55% of patients with metastatic lesions 
or recurrence whereas PET identified metastatic lesions in all 
the patients (100%) [47].
In general, the problem of PET is that exact localisation 
of an area with increased FDG uptake is often very difficult. 
PET/CT solves the problem of lesion localisation with the 
combination of metabolic and morphological imaging in 
the same patient position following image fusion. PET/CT 
provides additional information in 78% of patients compared 
with each modality alone [48]. In 10% of patients the com-
bination of PET/CT led to a change in patient management 
and was also able to reduce false positive results and pitfalls 
in 32% of all patients [48,49]. Patient-based sensitivity and 
specificity of PET/CT in detecting recurrence are 96% and 
89%, respectively [26].
Tumour markers whose blood levels seem to correlate 
with the tumour mass are useful tools in the follow-up of 
certain cancers. There is general agreement that a progres-
sive increase in a circulating tumour marker can represent 
an early sign of tumour recurrence [42]. Carcinoembryonic 
antigen (CEA) and cancer-antigen 15-3 (CA 15-3) are the 
most frequently used tumour markers for the detection of 
asymptomatic recurrences of breast cancers [50]. However, 
they lack specificity and elevation of their levels, although very 
suggestive, does not always prove the presence or recurrence 
of cancer and does not predict the number and localization 
of tumour sites [42,50].
Studies evaluated the impact of PET on the detection of 
recurrent breast cancer in patients with asymptomatic tumour 
marker increase (CA 15-3 >32U/ml, CEA >5ng/ml) but 
negative or equivocal other imaging modality results (bone 
scan,ultrasonography of breasts,mammography and CT of 
the chest and abdomen) [50]. Tumour marker-guided PET 
resulted in a sensitivity, specificity, accuracy, NPV and PPV of 
89%-96%, 75%-84%, 87%-90%, 82%-84% and 89%-96.2%, 
respectively [46,50-52]. All patients with false negative PET 
results also had negative findings on conventional imaging [10]. 
In a study, patients with a history of breast cancer underwent 
a PET/CT examination for restaging after a rise in tumour 
markers or suspicion of recurrent disease on the basis of 
clinical follow-up. In 36% of these patients, PET/CT led to a 
change in the therapeutic management [49].
C O N C L U S I O N S
During the past decade, the application of PET and PET/
CT has remarkably improved the management of cancer pa-
performed before and 7-10 days after initiation of tamoxifen 
therapy [41]. None of the responders developed a clinical flare 
reaction (i.e.progression of disease), but all demonstrated 
metabolic flare, with a mean increase in tumour SUVs of 
1.4±0.7. No evidence for flare was noted in the non-respond-
ers. The findings of a metabolic flare by FDG-PET early after 
institution of tamoxifen treatment appeared to predict respon-
siveness to anti-oestrogen therapy in patients with receptor-
positive breast cancer. The flare phenomenon has never been 
observed after chemotherapy but if chemohormonotherapy is 
performed, this finding should be kept in mind [33].
R E S T A G I N G – D E T E C T I O N  O F 
L O C O R E G I O N A L  A N D  D I S T A N T 
R E C U R R E N C E S 
Recurrence of disease at locoregional and distant sites 
occurs frequently in women who have undergone primary 
treatment for breast cancer. Recurrence occurs in up to 35% 
of patients by 10 years after mastectomy or breast-conserv-
ing therapy [42]. Routine follow-up after the completion of 
initial treatment for breast cancer is standard practice in most 
countries. Early detection and accurate restaging of recurrent 
cancer is important in the selection of the most appropriate 
treatment [14].
The conventional imaging modalities usually performed, 
such as mammography, CT, MRI and ultrasound, present 
some limitations in distinguishing between anatomical 
modifications like scarring and fibrosis, induced by therapy 
and relapse of disease. In contrast to morphological imaging, 
assessment of disease with PET is based on functional criteria 
and since functional changes precede anatomical changes, 
PET has the potential to detect viable tumour tissue early 
through its elevated glucose metabolism in comparison with 
surrounding normal tissues [21,31].
In several studies in patients with suspicious reccurences 
[26,27,43-46], the patient-based sensitivity, specificity, accu-
racy, positive predictive value (PPV) and negative predictive 
value (NPV) for PET were 85%-100%, 72%-82%, 84%-90%, 
82%-87% and 92% respectively. For comparison, the cor-
responding values for conventional imaging are 79%-84%, 
60%-94%, 74%-88%, 73% and 75% respectively [43,44]. 
In 15% of patients PET detected metastases outside of the 
axial field of view of MRI [43]. On a lesion basis the reported 
sensitivity is lower, due to the low sensitivity in detecting 
bone metastases (57%) [26]. In contrast in another study [26], 
PET correctly identified 97% of patients with lymph node 
metastases,83% with lung metastases and 100% with bone 
metastases.The majority of studies comparing the diagnostic 
accuracy of PET and bone scintigraphy for the evaluation of 
bone metastases in breast cancer patients have found PET to 
have a similar or higher sensitivity in the detection of osteolytic 
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tients and in cases of breast cancer, it is rapidly becoming part 
of the standard work-up of difficult cases in many centers. PET 
cannot be recommended as a screening tool for early breast 
cancer because of its limited spatial resolution and the often 
only moderate increase in glucose metabolism in breast cancer, 
which results in a low sensitivity for the detection of small 
carcinomas, micrometastases and small tumour-infiltrated 
lymph nodes. However, due to its high positive predictive 
value in revealing malignancy in metabolically active lesions 
and its ability to determine loco-regional lymph node status 
and detect distant metastases, PET or PET/CT using FDG is 
highly suitable in advanced stages of breast cancer.
Although FDG-PET has been used as a tracer in many 
tumour entities after radiation and chemotherapy, data in 
breast cancer are still scarce.The only indication where valid 
data are obtainable is the monitoring of primary chemotherapy 
in locally advanced breast cancer.
Several studies have shown that PET and PET/CT scan-
ning are highly accurate methods for whole-body restaging 
of patients with suspected breast cancer recurrence. PET and 
PET/CT, as metabolic diagnostic tools can complement the 
information provided by morphological imaging techniques 
and thereby increase the sensitivity and specificity in the 
evaluation of potential disease sites. Recent data indicate 
a rationale for the use of PET in cases of asymptomatically 
elevated tumour marker levels in the presence of negative or 
equivocal results of conventional imaging. The combination of 
PET and tumour marker assay seems to be usually sufficient 
for the early detection of breast cancer recurrence.
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